PT1864668E - Utilização de pró-fármacos para administração ocular intravítrea - Google Patents

Utilização de pró-fármacos para administração ocular intravítrea

Info

Publication number
PT1864668E
PT1864668E PT62909023T PT06290902T PT1864668E PT 1864668 E PT1864668 E PT 1864668E PT 62909023 T PT62909023 T PT 62909023T PT 06290902 T PT06290902 T PT 06290902T PT 1864668 E PT1864668 E PT 1864668E
Authority
PT
Portugal
Prior art keywords
ocular
prodrugs
intravitreous administration
intravitreous
administration
Prior art date
Application number
PT62909023T
Other languages
English (en)
Inventor
Laura Rabinovich-Guilatt
Gregory Lambert
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Publication of PT1864668E publication Critical patent/PT1864668E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
PT62909023T 2006-06-01 2006-06-01 Utilização de pró-fármacos para administração ocular intravítrea PT1864668E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06290901.5A EP1864667B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
US11/444,337 US20070281914A1 (en) 2006-06-01 2006-06-01 Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
EP06290902A EP1864668B1 (en) 2006-06-01 2006-06-01 Use of prodrugs for ocular intravitreous administration
US11/444,349 US20070280902A1 (en) 2006-06-01 2006-06-01 Method for treating eye disease or conditions affecting the posterior segment of the eye

Publications (1)

Publication Number Publication Date
PT1864668E true PT1864668E (pt) 2013-02-26

Family

ID=39712456

Family Applications (2)

Application Number Title Priority Date Filing Date
PT62909023T PT1864668E (pt) 2006-06-01 2006-06-01 Utilização de pró-fármacos para administração ocular intravítrea
PT62909015T PT1864667E (pt) 2006-06-01 2006-06-01 Uso de pró-fármacos para administração intravítrea ocular

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT62909015T PT1864667E (pt) 2006-06-01 2006-06-01 Uso de pró-fármacos para administração intravítrea ocular

Country Status (15)

Country Link
US (4) US20070280902A1 (pt)
EP (4) EP1864667B1 (pt)
JP (2) JP5284953B2 (pt)
KR (1) KR101408317B1 (pt)
CN (1) CN101553235B (pt)
AU (1) AU2007267079B2 (pt)
CA (1) CA2653902C (pt)
DK (2) DK2319517T3 (pt)
ES (1) ES2399976T3 (pt)
HK (2) HK1110219A1 (pt)
IL (1) IL195626A (pt)
PL (4) PL2322183T3 (pt)
PT (2) PT1864668E (pt)
SI (1) SI1864668T1 (pt)
WO (2) WO2007138113A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1864668T1 (sl) 2006-06-01 2013-04-30 Novagali Pharma S.A. Uporaba predzdravil za okularno intravitrealno dajanje
US10463609B2 (en) * 2007-10-05 2019-11-05 Wayne State University Dendrimers for sustained release of compounds
WO2009071594A1 (en) * 2007-12-04 2009-06-11 Novagali Pharma Sa Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
UA111867C2 (uk) * 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
CN104125830B (zh) * 2012-02-10 2018-01-16 台湾微脂体股份有限公司 用以减少眼用类固醇的并发症的药物组合物
CN110944668A (zh) 2017-06-16 2020-03-31 学校法人同志社 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用
EP3707193A1 (en) 2017-11-10 2020-09-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
HRP20231000T1 (hr) * 2020-02-25 2023-12-08 Labomed Pharmaceutical Company S.A. Oralne otopine koje sadrže fludrokortizon acetat
WO2022058325A1 (en) 2020-09-16 2022-03-24 Santen Sas Oil-in-water emulsions for intravitreal administration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609726B2 (ja) 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS5716818A (en) 1981-04-25 1982-01-28 Green Cross Corp:The Steroid fatty emulsion
AU531588B2 (en) 1981-08-17 1983-09-01 Yoshitomi Pharmaceutical Industries, Ltd. Emulsifying water-insoluble steroid
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
AU4201189A (en) 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH05132498A (ja) * 1991-11-08 1993-05-28 Asahi Glass Co Ltd ステロイド誘導体およびその製剤
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
ATE198880T1 (de) * 1993-08-02 2001-02-15 Commw Scient Ind Res Org Therapeutische verbindung - fettsäurekonjugate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US6114319A (en) 1997-05-14 2000-09-05 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
IL121647A (en) * 1997-08-28 2001-07-24 Pharmateam Dev Ltd Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
EP1020194A4 (en) 1997-10-01 2003-05-21 Wakamoto Pharma Co Ltd OIL / WATER EMULSION COMPILATIONS
JP2000212067A (ja) * 1999-01-19 2000-08-02 Towa Yakuhin Kk 薬物含有エマルジョン製剤
CN100335036C (zh) 2001-11-01 2007-09-05 耶路撒冷希伯来语大学依苏姆研究开发公司 用于干眼症治疗的方法和组合物
US20040151754A1 (en) * 2002-12-20 2004-08-05 Control Delivery Systems, Inc. Steroid suspensions for intraocular use
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
SI1663185T1 (sl) * 2003-09-22 2009-04-30 Onepharm Res & Dev Gmbh Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
DE602004022523D1 (de) * 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
CA2582096C (en) * 2004-10-01 2014-01-07 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20060094700A1 (en) * 2004-11-02 2006-05-04 Allergan, Inc. Heat sterilization of a steroid in the presence of phosphate
JP5008571B2 (ja) * 2004-11-09 2012-08-22 ノバガリ ファルマ エスア 免疫抑制剤を含む眼科用エマルジョン
CN1905012A (zh) 2005-07-31 2007-01-31 新科实业有限公司 具有微驱动器的磁头折片组合及其磁盘驱动装置
US8109884B2 (en) 2005-09-23 2012-02-07 Kitchener Clark Wilson Dynamic metabolism monitoring system
SI1864668T1 (sl) 2006-06-01 2013-04-30 Novagali Pharma S.A. Uporaba predzdravil za okularno intravitrealno dajanje

Also Published As

Publication number Publication date
PL1864667T3 (pl) 2014-01-31
WO2007138114A1 (en) 2007-12-06
KR20090031373A (ko) 2009-03-25
EP1864667A1 (en) 2007-12-12
IL195626A0 (en) 2009-09-01
PL2322183T3 (pl) 2015-01-30
CN101553235B (zh) 2012-12-05
US20070280902A1 (en) 2007-12-06
WO2007138113A1 (en) 2007-12-06
JP2009538879A (ja) 2009-11-12
AU2007267079A1 (en) 2007-12-06
EP2322183A1 (en) 2011-05-18
EP2322183B1 (en) 2014-10-22
JP5284953B2 (ja) 2013-09-11
IL195626A (en) 2017-05-29
EP1864667B1 (en) 2013-09-04
HK1110221A1 (en) 2008-07-11
CA2653902C (en) 2015-03-17
DK2319517T3 (da) 2013-12-09
KR101408317B1 (ko) 2014-06-17
JP5455624B2 (ja) 2014-03-26
PL2319517T3 (pl) 2014-01-31
CN101553235A (zh) 2009-10-07
AU2007267079B2 (en) 2013-01-31
PL1864668T3 (pl) 2013-04-30
DK1864668T3 (da) 2013-03-04
CA2653902A1 (en) 2007-12-06
EP2319517B1 (en) 2013-09-11
JP2009538880A (ja) 2009-11-12
EP1864668A1 (en) 2007-12-12
SI1864668T1 (sl) 2013-04-30
US8227452B2 (en) 2012-07-24
EP2319517A1 (en) 2011-05-11
PT1864667E (pt) 2013-11-18
US20070281913A1 (en) 2007-12-06
HK1110219A1 (en) 2008-07-11
EP1864668B1 (en) 2012-11-21
US20070281914A1 (en) 2007-12-06
ES2399976T3 (es) 2013-04-04
US20070280995A1 (en) 2007-12-06
US9192567B2 (en) 2015-11-24

Similar Documents

Publication Publication Date Title
HK1110221A1 (en) Use of prodrugs for ocular intravitreous administration
EP2963031A3 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
MX2007008848A (es) Metodos y composiciones para el tratamiento de desordenes oculares.
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2007002390A3 (en) Compositions and methods for modulation of smn2 splicing
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
MX337100B (es) Compuestos alcoxi para el tratamiento de enfermedades.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
EP2386299A3 (en) 1-Amino-Alkylcyclohexane derivatives for the treatment of cochlear tinnitus
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
EP3069612A3 (en) Dithiol compounds, derivatives, and uses therefor
SI1861100T1 (sl) 3,11b-cis-dihidrotetrabenazin za zdravljenje proliferacijske bolezni ali vnetja
SI2380584T1 (sl) Imunostimulatorni postopek
MX2010000351A (es) Compuestos derivados de alquinil fenilo para tratar enfermedades y desordenes oftalmicos.
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
WO2008137780A3 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
WO2011031518A3 (en) Femoral guide for acl repair having reduced profile for left/right knee configurations
WO2011037837A3 (en) Vaginal vault suspension device and method
EP1768656A4 (en) TREATMENT OF OCULAR DISEASES
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2007109174A3 (en) Compositions and methods for modulation of mcl-1 expression
WO2008011473A3 (en) Compositions and their uses directed to hbxip
WO2007104933A8 (en) Chemical compounds